Advanced Anti-Fungal Agent


Recent studies indicate that the mortality rate for people with compromised immune systems who contract systemic fungal infections is 38 percent. In the US alone, this group, consisting of those with HIV, cancer, bone marrow transplant and organ transplant patients, number 9 million. The total market opportunity for treatment grows at 11% per year. Leading treatments known as "azole" category anti-fungals are becoming less effective due to growing fungal resistance.  Infections involving the Candida species rank as the fourth most common type of infection that originates in a hospital.  Candida is also responsible for a range of other, less serious human hygiene issues, including oral cavity infections, yeast infections and infections of the urethrae, ear canal, the respiratory system, and various skin and mucosal surfaces.

To address these issues, University of Arkansas researchers have synthesized an analog to a naturally occurring antifungal compound. Extensive testing shows significantly higher efficacy than other possible treatments for the fungus Candida Albicans. To see the published patent application, go to this link:



Patent Information:
App Type Country Serial No. Patent No. File Date Issued Date Expire Date
Nationalized United States 14/777,321 9,556,226 9/15/2015 1/31/2017  
For Information, Contact:
Mark Swaney
Technology Licensing Officer
University of Arkansas
Suresh Kumar
Anna Daily
David Mcnabb
© 2018. All Rights Reserved. Powered by Inteum